Tenon Medical, Inc. (TNON)

Expanded Global Portfolio Enhances Competitive Position and Supports Long-Term Growth Strategy LOS GATOS, CA / ACCESS Newswire / February 18, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company redefining care for patients suffering from sacro-pelvic disorders, today announced a strategic expansion of its U.S. intellectual property portfolio following receipt of Notices of Allowance from the United States Patent and Trademark Office (USPTO) for multiple patent applications expected to issue in 2026. These newly allowed claims will further strengthen the Company's growing patent portfolio and build upon the (10) ten patents issued in 2025, including (5) five issued by the USPTO and (5) five issued internationally.

Tenon Medical (NASDAQ: TNON - Get Free Report) and Positron (OTCMKTS:POSC - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings. Institutional and Insider Ownership 22.7% of Tenon Medical

Fourth Quarter 2025 Revenue of $1.45 to $1.48 Million, representing growth of ~90% year over year Full Year 2025 Revenue of $3.91 to $3.94 Million, representing growth of ~20% year over year LOS GATOS, CA / ACCESS Newswire / February 5, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company redefining care for patients suffering from sacro-pelvic disorders, today announced plans to release financial results for the fourth quarter and full year 2025 ended December 31, 2025 after market close on Thursday, March 19, 2026. The Company will also hold a conference call on the same day at 4:30 p.m.

Tenon Medical (NASDAQ: TNON - Get Free Report) and Waters (NYSE: WAT - Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations. Institutional and Insider Ownership 22.7% of Tenon Medical shares

Beta Bionics, Inc. (NASDAQ: BBNX - Get Free Report)'s stock price dropped 9.2% during mid-day trading on Monday after Wall Street Zen downgraded the stock from a hold rating to a sell rating. The stock traded as low as $17.83 and last traded at $18.28. Approximately 378,461 shares traded hands during mid-day trading, a decline of

Tenon Medical, Inc. (NASDAQ: TNON - Get Free Report)'s share price dropped 1.7% on Monday. The company traded as low as $0.94 and last traded at $0.9531. Approximately 95,534 shares changed hands during mid-day trading, an increase of 39% from the average daily volume of 68,767 shares. The stock had previously closed at $0.97. Analyst

Beta Bionics (NASDAQ: BBNX - Get Free Report) and Tenon Medical (NASDAQ: TNON - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, risk and dividends. Insider and Institutional Ownership 22.7% of Tenon

~ Procedures Completed in Various Spine Centers of Excellence Throughout the Country Including Florida, Arizona, Ohio, and Texas ~ ~ SImmetry+ combines 3D-printed titanium implants, a robust joint decorticator, and a streamlined bone graft delivery system to offer treatment solutions aligned with established fusion principles ~ ~ Immediate revenue impact opportunity while significantly advancing Tenon's competitive position in redefining SI joint fusion with a multi-approach portfolio in rapidly expanding sacro-pelvic market ~ LOS GATOS, CA / ACCESS Newswire / December 4, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company redefining care for patients suffering from sacro-pelvic disorders, today announced the completion of the first clinical procedures utilizing the Company's new SImmetry+ SI Joint Fusion System. Ali Araghi, DO, Orthopedic Spine Surgeon in Phoenix, Arizona, Brian Fiani, DO Board Certified Neurosurgeon in Tampa, FL.

IQVIA (NYSE: IQV - Get Free Report) and Tenon Medical (NASDAQ: TNON - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership. Analyst Recommendations This is a summary of recent recommendations

LOS GATOS, CA / ACCESS Newswire / November 14, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacro-pelvic disorders, today announced the successful closing of its previously announced at-the-market private investment in public equity (the "PIPE") financing. As part of the closing of the PIPE, Tenon Medical has issued an aggregate of 2,217,904 shares of common stock (the "Issued Shares") along with warrants (the "PIPE Warrants") to purchase an equal number of shares.

Tenon Medical, Inc. ( TNON ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Steven Foster - CEO, President & Director Kevin Williamson - Chief Financial Officer Conference Call Participants Scott Henry - Alliance Global Partners, Research Division Thomas McGovern Presentation Operator Greetings, and welcome to the Tenon Medical Third Quarter 2025 Financial Results and Corporate Update Conference Call. As a reminder, this call is being recorded.

~ Record revenue of $1.2 million, a 32% year-over-year increase, reflecting record volume in Catamaran® SI Joint Fusion System procedures and the addition of SImmetry® SI Joint Fusion Product Sales ~ ~ SImmetry®+ alpha launch in Q4 2025 advances strategic portfolio ~ ~ Foundation set for sustained growth through portfolio diversification, commercial expansion and operational alignment ~ ~ Subsequent to quarter end the Company announced the pricing of a PIPE financing with an industry supportive investor cohort raising total gross proceeds of $2.85 million ~ LOS GATOS, CA / ACCESS Newswire / November 13, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company transforming care for patients suffering with certain sacro-pelvic disorders, today reported record financial results for the third quarter ended September 30, 2025. Financial Results and Business Updates Record revenue of $1.2 million, compared to $0.9 million in the third quarter of 2024.

~ Strategically Placed PIPE With Industry Supportive Investor Cohort ~ LOS GATOS, CA / ACCESS Newswire / November 11, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacro-pelvic disorders, today announced the pricing of an at-the-market private investment in public equity (the "PIPE") financing with several accredited investors for total gross proceeds of $2,850,000. The PIPE is designed to provide accretive capital through participation from strategic industry partners and members of Tenon's management team.

LOS GATOS, CA / ACCESS Newswire / November 3, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacro-pelvic disorders, today announced plans to release financial results for the third quarter 2025 ended September 30, 2025 after market close on Thursday, November 13, 2025. The Company will also hold a conference call on the same day at 4:30 p.m.

~Clearance expands Company's competitive advantage of clinically proven, minimally invasive technologies to treat debilitating SI joint conditions from multiple surgical approaches~ ~SImmetry+'s New 3D printed titanium implants, robust joint decorticator, and simple bone graft delivery system provides physicians treatment options rooted in established fusion principles~ ~Company initiating alpha launch of SImmetry® + with select group of physician users to provide initial feedback to support broader launch~ LOS GATOS, CA / ACCESS Newswire / October 21, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacro-pelvic disorders, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the SImmetry+ SI Joint Fusion System. The SImmetry+ System is indicated for sacroiliac (SI) joint fusion for conditions including sacroiliac joint disruptions and degenerative sacroiliitis, providing physicians with treatment options rooted in established fusion principles.

~ Clinically Significant Patient Outcomes Demonstrate Improvements in Pain (VAS) and Disability (ODI), Along with High Patient Satisfaction and Safety Profile at 12-Month Analysis ~ ~ 83% of Patients Reaching 12 Month Radiographic CT Follow-up Showed Unequivocal Evidence of Fusion with Bridging Bone Across the SI Joint as Identified by an Independent Radiology Reviewer ~ ~Compelling Clinical Data from Catamaran Mainsail Study and Recently Acquired SiVantage Technology Portfolio Expected to Drive Exponential Growth in Rapidly Expanding Sacro-Pelvic Fusion Market ~ LOS GATOS, CA / ACCESS Newswire / September 4, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacro-pelvic disorders, today announced the second interim analysis publication from its ongoing MAINSAIL™ study, a prospective, single-arm, multi-center, post-market clinical trial evaluating clinical and radiographic outcomes in adult patients with sacroiliac (SI) joint disruptions or degenerative sacroiliitis treated with the Catamaran® SI Joint Fusion System. The Mainsail study is designed to enroll up to 50 patients, each followed for up to 24 months.